SAN
DIEGO, Jan. 6, 2025 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) will present at the
43rd Annual J.P. Morgan Healthcare Conference at
8:15 a.m. Pacific Time on Monday
January 13, 2025 in San Francisco.
Kyle Gano, Chief Executive Officer,
will present at the conference.
The live presentation will be webcast and may be accessed on the
Company's website under Investors at www.neurocrine.com. A replay
of the presentation will be available on the website approximately
one hour after the conclusion of the events and will be archived
for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is
a leading neuroscience-focused, biopharmaceutical company with a
simple purpose: to relieve suffering for people with great needs,
but few options. We are dedicated to discovering and developing
life-changing treatments for patients with under-addressed
neurological, neuroendocrine, and neuropsychiatric disorders. The
company's diverse portfolio includes FDA-approved treatments for
tardive dyskinesia, chorea associated with Huntington's disease,
classic congenital adrenal hyperplasia, endometriosis* and uterine
fibroids*, as well as a robust pipeline including multiple
compounds in mid- to late-phase clinical development across our
core therapeutic areas. For three decades, we have applied our
unique insight into neuroscience and the interconnections between
brain and body systems to treat complex conditions. We relentlessly
pursue medicines to ease the burden of debilitating diseases and
disorders, because you deserve brave science. For more information,
visit neurocrine.com, and follow the company on LinkedIn, X
(formerly Twitter) and Facebook. (*in collaboration with
AbbVie)
The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE
SCIENCE are registered trademarks of Neurocrine Biosciences,
Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302343441.html
SOURCE Neurocrine Biosciences, Inc.